unknown node
unknown node
unknown node
unknown node
- unknown node
- unknown node
- unknown node
- unknown node
unknown node
unknown node
unknown node
unknown node
unknown node
- unknown node
- unknown node
- unknown node
- unknown node
unknown node
STI & AMR · Molecular Assays · Application Insights · Lab Operations
Culture-free resistance detection: where rapid molecular AMR markers fit in stewardship
Key takeaways
Rapid molecular AMR markers earn their place by compressing isolation and de-escalation decisions from days to hours. They complement, not replace, culture-based susceptibility testing — and they deliver value only when the assay menu is matched to a specific decision point in the workflow.
- Markers change isolation and de-escalation timelines; culture remains the reference standard.
- A detected gene is not a phenotype — label and communicate marker results as such.
- Place assays at decision points: admission screening, positive blood cultures, high-risk transfers.
- Revisit the marker menu annually against your own antibiogram and regional surveillance.
Target audienceLab Director, Infectious Disease, Procurement
Review and references
Compiled from public manufacturer materials and regulatory sources. Not independently verified and not reviewed by a named clinician.
2026-10-06
2026-10-06
professional use
FAQ
Common questions
Do molecular resistance markers replace culture?
No. They complement culture. Markers answer faster for the specific genes they assay, but culture and susceptibility testing remain the reference standard and quantify what markers cannot.
Which resistance markers are most commonly run on molecular platforms?
MRSA (mecA/mecC), VRE (vanA/vanB), carbapenemase families (KPC, NDM, VIM, IMP, OXA-48-like), and rifampicin-resistance mutations for tuberculosis are the established, guideline-endorsed set.
Can a negative marker screen stop empiric therapy?
Not by itself. A negative result excludes only the mechanisms assayed, and screening specimens can contain organisms below detection or mixed populations. Marker results inform, but clinical decisions still require the full picture.
How should we choose which markers to run?
Start from your institution’s antibiogram and regional surveillance data, then place assays where a faster answer changes a decision — admission screening, positive blood cultures, or outbreak investigations.
Explore more
Same category
Viral hepatitis elimination: a procurement checklist for viral-load platforms
A procurement checklist for HBV/HCV viral-load platforms in elimination programmes: dynamic range, Genediscipline, lot supply at programme volume, and regulatory pathways that survive aud…
Same categoryNAT yield testing for mid-size blood banks: what actually drives the economics
The cost drivers of nucleic acid amplification testing for blood screening at mid-size scale: pooling strategy, yield-window claims, workflow integration, and what to verify before signing.
Same categoryCase study: extending STI molecular testing from a referral lab into community points of care
A composite case on decentralising STI molecular testing: what changes when NAATs leave the referral lab, which controls keep quality intact, and how procurement scored the pilot.